Core Insights - Pluri Inc. is recognized as a promising long-term penny stock with significant upside potential, particularly following its recent collaboration with a Mexican public body to advance cell-based coffee manufacturing [1][3]. Group 1: Collaboration and Innovation - Pluri's subsidiary, Coffeesai Ltd., has entered into a collaboration agreement with Instituto del Café de Chiapas/INCAFECH to promote cell-based coffee production in Chiapas, Mexico, which is known as the leading coffee-growing region in the country [1][2]. - The partnership aims to establish Chiapas as a hub for innovation in coffee manufacturing, leveraging state support to enhance the commercialization of cell-based coffee products [1][2]. Group 2: Business Model and Revenue Generation - Coffeesai utilizes Pluri's proprietary 3D cell expansion platform and two decades of expertise to develop sustainable cell-based coffee products, outlining a multi-phase, capital-light roadmap to mitigate commercialization risks [2][3]. - The collaboration is expected to create shareholder value through potential non-dilutive revenues from licensing and technology transfer, as well as recurring revenue streams from royalty-bearing models and joint ventures [3]. Group 3: Company Overview - Pluri Inc. is a biotechnology company focused on researching, developing, and manufacturing cell-based products and related technologies across various industries [4].

Company Leadership Transition - DarioHealth Corp. announced the retirement of Chief Financial Officer Zvi Ben-David, effective May 15, 2025 [1][2] - Chen Franco-Yehuda has been appointed as the new Chief Financial Officer, Treasurer, and Secretary, set to assume the role upon Mr. Ben-David's retirement [2][3] - Mr. Ben-David will assist the company in an advisory capacity until the end of June 2025 to ensure a smooth transition [2] New CFO's Background - Chen Franco-Yehuda brings extensive financial leadership experience, particularly in corporate finance, capital markets, and strategic growth initiatives [3] - She previously served as CFO at Pluri Inc., where she led financial strategy and secured substantial capital through various fundraising rounds [4] - Franco-Yehuda has a background as an Audit/Assurance Manager at PwC and is a licensed CPA in Israel [5] Company Growth and Strategy - Under Mr. Ben-David's leadership, DarioHealth transformed from a single-condition solution provider to a comprehensive multi-condition digital health platform [6] - The company has expanded its offerings across various health conditions, including diabetes, hypertension, mental health, weight management, and musculoskeletal care [6] - DarioHealth aims to leverage Franco-Yehuda's expertise to continue driving innovation and growth in the digital health sector [6][7]

Core Insights - Pluri Inc. has received a patent from the U.S. Patent and Trademark Office for its immune cell expansion technologies, specifically for MAIT cells, which are important for fighting infections and tissue repair [1][4] - The company has also secured a corresponding patent in Israel, bringing its total intellectual property estate to over 250 patents [1] - Pluri's MAIT cells, derived from the placenta, are positioned as a promising solution for treating solid tumors, addressing a significant unmet medical need in immunotherapy [2][5] Intellectual Property and Technology - The newly granted patents focus on large-scale culturing and activation of immune cells using Pluri's proprietary 3D cell expansion bioreactors [3][7] - Pluri's 3D cell expansion technology mimics the natural environment of lymph nodes, allowing for efficient and high-quality immune cell expansion [8] Market Potential - The global immune cell engineering market is projected to reach approximately $11.7 billion by 2030, while the global cancer immunotherapy market is estimated at $136 billion in 2025 [7] - Pluri's MAIT platform not only supports the expansion of MAIT cells but also Tumor Infiltrating Lymphocytes (TILs), broadening the scope of potential therapies in cancer immunotherapy [7] Strategic Vision - The CEO of Pluri emphasizes the potential of MAIT cells in immunotherapy and the company's capability to scale production, positioning it for collaborations that could deliver immune therapies to patients [4] - Pluri aims to develop its proprietary placental-derived MAIT cell immunotherapy platform to revolutionize solid tumor treatment and support other companies in commercializing their immunotherapy treatments [4][6]

Core Viewpoint - Pluri Inc. has entered into an exclusive collaboration with Hemafund Ltd. to develop and distribute PLX-R18 cell therapy as a countermeasure against Hematopoietic Acute Radiation Syndrome (H-ARS) in Ukraine, in response to recent nuclear threats [1][3][5] Collaboration Agreement - The collaboration will last for an initial three years, with the possibility of a three-year extension, focusing on stockpiling and distribution of PLX-R18 [1][2] - Pluri will produce PLX-R18, while Hemafund will utilize its biostorage and logistics expertise to ensure compliance with local regulations [2][9] Strategic Goals - The collaboration aims to secure external funding to establish an initial capacity of 12,000 doses of PLX-R18, sufficient to treat 6,000 individuals [4][5] - Hemafund will manage the storage and logistics of PLX-R18, ensuring rapid deployment in emergencies [4][9] Financial Implications - If successful, the collaboration could generate over $100 million in value for both parties based on the estimated cost per dose and projected stockpile [5][8] Context and Urgency - The collaboration is a proactive response to recent escalations in nuclear threats, highlighting the urgent need for effective radiation countermeasures in Ukraine [3][10] Company Background - Hemafund specializes in the preservation of umbilical cord blood and operates advanced cryostorage facilities in Ukraine [11] - Pluri is focused on developing cell-based products and solutions across various sectors, including regenerative medicine and food technology [12]

Core Viewpoint - Pluri Inc. has entered into an exclusive collaboration with Hemafund Ltd. to develop and distribute PLX-R18 cell therapy as a countermeasure against Hematopoietic Acute Radiation Syndrome (H-ARS) in Ukraine, in response to recent escalations in regional nuclear threats [1][3]. Group 1: Collaboration Agreement - The collaboration agreement is effective for an initial period of three years, with the possibility of a three-year extension [1]. - Pluri will produce and supply PLX-R18, while Hemafund will utilize its biostorage and logistics expertise to ensure compliance with local regulations [2][9]. - The collaboration aims to secure external funding to build an initial capacity of 12,000 doses of PLX-R18, sufficient to treat 6,000 individuals [4][5]. Group 2: Strategic Goals - The collaboration addresses Ukraine's urgent need for radiation countermeasures and ensures secure storage and rapid deployment of treatments [8]. - It seeks to attract public and private funding to support the development and accessibility of PLX-R18 [9]. - The collaboration may potentially generate over $100 million in value for both parties based on the estimated cost per dose and projected stockpile [5]. Group 3: Context and Need - The collaboration is a response to recent incidents, including a Russian drone strike on the Chernobyl nuclear power plant, highlighting the need for effective radiation countermeasures [3]. - H-ARS is caused by exposure to high levels of ionizing radiation, leading to severe health risks [6].